Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4849033
Max Phase: Preclinical
Molecular Formula: C13H12ClN5S
Molecular Weight: 305.79
Molecule Type: Unknown
Associated Items:
ID: ALA4849033
Max Phase: Preclinical
Molecular Formula: C13H12ClN5S
Molecular Weight: 305.79
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cn1cc(Cc2cccs2)c(-c2cc(Cl)nc(N)n2)n1
Standard InChI: InChI=1S/C13H12ClN5S/c1-19-7-8(5-9-3-2-4-20-9)12(18-19)10-6-11(14)17-13(15)16-10/h2-4,6-7H,5H2,1H3,(H2,15,16,17)
Standard InChI Key: VPCGXMWBHSCODI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 305.79 | Molecular Weight (Monoisotopic): 305.0502 | AlogP: 2.77 | #Rotatable Bonds: 3 |
Polar Surface Area: 69.62 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 1.31 | CX LogP: 3.58 | CX LogD: 3.58 |
Aromatic Rings: 3 | Heavy Atoms: 20 | QED Weighted: 0.76 | Np Likeness Score: -2.16 |
1. Fushimi M, Buck H, Balbach M, Gorovyy A, Ferreira J, Rossetti T, Kaur N, Levin LR, Buck J, Quast J, van den Heuvel J, Steegborn C, Finkin-Groner E, Kargman S, Michino M, Foley MA, Miller M, Liverton NJ, Huggins DJ, Meinke PT.. (2021) Discovery of TDI-10229: A Potent and Orally Bioavailable Inhibitor of Soluble Adenylyl Cyclase (sAC, ADCY10)., 12 (8.0): [PMID:34413957] [10.1021/acsmedchemlett.1c00273] |
Source(1):